| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Incredible Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $97.08M | Series B | 8/17/2022 | $80M | $1.65B | $85.10 | Base10 Partners, Obvious Ventures, Workday, Andre Iguodala, Chano Fernandez, 444 Capital Fund, Andreessen Horowitz, Kaiser Permanante | ||||
 | IntelyCare | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $117.50K | -- | 1 | Not available | -- | -- | $232.77M | Series CR-B | 12/23/2025 | $25.64M | $3.21B | $41.67 | Undisclosed Investors | ||||
 | Olive | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $837.59M | Series H | 7/1/2021 | $450.32M | $4B | $14.13 | Vista Equity Partners, Base10 Partners Advancement Initiative | ||||
 | 23andMe | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $876.61M | Series F-1 | 12/23/2020 | $385M | $2.59B | $17.35 | GlaxoSmithKline, NewView Capital, Sequoia Capital | ||||
 | Clarify | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $408.35M | Series D-1 | 4/5/2022 | $165.63M | $1.45B | $9.32 | SoftBank, BlackRock, Memorial Hermann Health System, Insight Partners, Spark Capital, KKR, Aspenwood Ventures, Rivas Capital, Sigmas Group | ||||
 | Intarcia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $961.46M | Series EE | 9/15/2016 | $475.68M | $3.94B | $60.00 | Baillie Gifford, Luxin Venture Capital, Fidelity Investments, RA Capital Management, Foresite Capital Management, The Pritzker Organization, The Baupost Group | ||||
 | Modern Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $170.58M | Series D | 2/11/2021 | $74M | $1.17B | $44.05 | Founders Fund, Lachy Groom | ||||
 | One Medical Group | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $437.68M | Series I | 8/22/2018 | $250M | $1.5B | $12.43 | The Carlyle Group | ||||
 | Reify Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $490.2M | Series D | 4/21/2022 | $230.78M | $4.78B | $11.11 | Altimeter Capital, Coatue Management, Dragoneer Investment Group, ICONIQ Growth, Adams Street, Battery Ventures | ||||
 | Thyme Care | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $233.75M | Series D | 9/25/2025 | $75.21M | $1B | $7.63 | CVS Health Ventures, Foresite Capital, Andreessen Horowitz, Concord Health Partners, Town Hall Ventures, AlleyCorp, Frist Cressey Ventures, Morgan Health, Humana, Texas Oncology, Memorial Hermann Health System | ||||
 | TrueBinding | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $166.08M | Series D-1 | 3/17/2023 | $46.08M | $1.21B | $5.08 | Wangsu | ||||
 | CareBridge Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190.85M | Series C | 6/8/2022 | $140M | $1.15B | $48.24 | Oak HC/FT, Optum Ventures, CVS Ventures, Anthem, HLM Venture Partners | ||||
 | Clover Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $676.33M | Series D | 5/10/2017 | $130M | $1.23B | $9.38 | Baillie Gifford, Expanding Capital, First Round Capital, Greenoaks Capital, GV, Palm Drive Capital, Sequoia Capital, Toba Capital, Western Technology Investment | ||||
 | Immunai | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.22M | Series C-1 | 10/27/2021 | $204.34M | $1.15B | $186.65 | Koch Disruptive Technologies, Talos VC, 8VC, Alexanria Venture Investments, Piedmont, ICON | ||||
 | Inscripta | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $459.69M | Series E | 4/5/2021 | $150M | $1.32B | $8.83 | Fidelity, T. Rowe Price | ||||
 | Nutcracker Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $244.06M | Series C | 3/14/2022 | $167.76M | $1.09B | $10.75 | ARCH Venture Partners | ||||
 | Treeline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.1B | Series A-2 | 9/3/2025 | $200.1M | $1.83B | $8.61 | Access Industries, ARCH Venture Partners, OrbiMed, GV, KKR, T. Rowe Price Associates, Ajax Health, Casdin Capital, Fidelity, Aisling Capital, Rock Springs Capital, Exor | ||||
 | American Well | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $674M | Series C | 5/20/2020 | $617M | $1.03B | $45.00 | InVenture Partners, Anthem, Teva Pharmaceutical Industries, Allianz X, Philips, Martin Ventures, Hanaco Venture Capital, Cito Ventures, ADIP, Echo Health Ventures, McKesson Ventures, Waterline Ventures, Westway Capital, SV Health Investors | ||||
 | Lyell | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.04B | Series C | 3/5/2020 | $493M | $2.5B | $11.49 | ARCH Venture Partners, Foresite Capital, Milky Way Investments | ||||
 | Proteus Digital Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $397.36M | Series H | 4/15/2016 | $50M | $1.64B | $15.80 | Undisclosed Investors | ||||
 | Adaptive Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $561.37M | Series F-1 | 1/4/2018 | $45M | $1.35B | $10.67 | Microsoft | ||||
 | Auris Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $738.23M | Series D-1 | 11/28/2018 | $220.42M | $2.13B | $0.21 | Partner Fund Management, Wellington Management, D1 Capital Partners, Senator Investment Group, Mithril Capital Management, Lux Capital, Viking Global Investors | ||||
 | EQRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $813.88M | Series B | 1/11/2021 | $570M | $1.66B | $2.74 | GV, Bain Capital Life Sciences, Andreessen Horowitz, ARCH Venture Partners, Arboretum Ventures, Casdin Capital, Nextech, Section 32 | ||||
 | Ginger | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $232.76M | Series E | 3/24/2021 | $100M | $1.12B | $44.80 | Blackstone Growth, Kaiser Permanente Ventures, Cigna Ventures, Bessemer Venture Partners, Advance Ventures Partners, Khosla Ventures, Health Velocity Capital, City Light Capital, WP Global Partners | ||||